SEC Tracker
Get the app
ENTA · XBRL financial data

Enanta Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ENTA's year ends in late September)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers18,932*18,00317,05417,97114,607*16,95914,92618,31415,125*18,61517,15914,359
Research and development36,167*36,37135,58528,74230,778*27,65628,06527,21023,809*20,85919,44322,126
General and administrative13,795*16,51814,23513,41413,683*12,84611,3889,9979,702*9,0099,5689,469
Operating income (loss)(31,030)*(34,886)(32,766)(24,185)(29,854)*(23,543)(24,527)(18,893)(18,386)*(11,253)(11,852)(17,236)
Interest expense3,151*3,4412,5632,3552,581*1,9621,7141,6182,387*3,0833,3164,130
Income tax expense (benefit)(1,410)*(622)(363)(395)(363)*(416)(1,305)2932*24736
Net income (loss)(28,107)*(33,407)(31,157)(22,658)(28,823)*(22,290)(22,644)(18,255)(18,700)*(11,938)(13,091)(19,501)
Earnings per share, basic USD per share—(1.58)(1.47)(1.07)—(1.05)(1.06)(0.85)—(0.42)(0.45)(0.67)
Earnings per share, diluted USD per share—(1.58)(1.47)(1.07)—(1.05)(1.06)(0.85)—(0.42)(0.45)(0.67)
Weighted average shares, basic thousands of shares—21,08821,16721,180—21,23821,35521,377—28,74829,04029,090
Weighted average shares, diluted thousands of shares—21,08821,16721,180—21,23821,35521,377—28,74829,04029,090

Balance sheet

CSV

Fiscal quarters (ENTA's year ends in late September)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents85,38839,93363,54235,77537,23384,34960,21344,81232,29837,43734,92833,419
Marketable securities284,522297,218236,768194,310210,953132,342133,162159,299156,566148,412128,846156,087
Marketable securities, non-current0——42,510————056,05563,23821,987
Accounts receivable8,6148,1737,7568,1766,6467,7186,7928,3336,8828,4937,8096,534
Prepaid and other current assets13,26313,24510,93215,26012,41310,6848,85710,2408,5904,3426,8107,579
Total current assets422,791390,303351,029286,584299,852268,145242,860222,708204,336198,684178,412203,619
Property and equipment, net11,91912,11915,47925,05132,68837,36837,57236,61735,39534,30833,11431,942
Right-of-use asset22,79421,34442,89441,21140,65839,67539,10338,25037,54937,00336,43635,852
Total assets462,275428,499413,557398,821376,652348,642322,993301,029280,732329,503314,704296,870
Accounts payable4,0979,3266,72610,6758,0024,7264,7563,5471,9481,8854,3633,293
Accrued liabilities18,33911,60310,63012,83013,54710,5758,31410,85312,7517,5756,85910,183
Total current liabilities62,78762,40754,60858,23157,53549,05045,94744,54948,55544,72846,44254,166
Lease liability, non-current21,23820,52443,41248,13653,94356,45356,53655,65654,75753,78252,77751,750
Total liabilities245,540236,615247,443249,906247,838236,826229,455221,750216,015202,912198,117195,802
Accumulated deficit(206,995)(240,402)(271,559)(294,217)(323,040)(345,330)(367,974)(386,229)(404,929)(416,867)(429,958)(449,459)
Total stockholders' equity216,735191,884166,114148,915128,814111,81693,53879,27964,717126,591116,587101,068
Total liabilities and equity462,275428,499413,557398,821376,652348,642322,993301,029280,732329,503314,704296,870
Common shares outstanding (cover page) thousands of shares21,05921,15621,17921,18921,19421,33321,37721,37828,86329,01929,07829,125

Cash flows

CSV

Fiscal quarters (ENTA's year ends in late September)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(28,107)*(33,407)(31,157)(22,658)(28,823)*(22,290)(22,644)(18,255)(18,700)*(11,938)(13,091)(19,501)
Stock-based compensation6,716*8,0995,561*5,417*7,718*5,6664,688*4,177*4,034*3,8103,748*3,683*
Net cash from operating activities(21,602)*(24,988)(28,601)*(14,775)*(10,400)*(16,801)(13,488)*17,506*(6,489)*(11,699)(7,156)*(9,972)*
Purchases of property and equipment1,368*7871,668*6,542*8,951*8,7452,538*155*1,458*14315*7*
Net cash from investing activities11,836*(13,117)58,624*(6,345)*19,073*68,903(4,369)*(26,483)*2,296*(47,298)11,942*14,005*
Net cash from financing activities(23)*(7,350)(6,414)*(6,647)*(7,215)*(4,986)(6,887)*(6,424)*(8,321)*64,136(7,295)*(5,542)*
Net change in cash(9,789)*(45,455)23,609*(27,767)*1,458*47,116(24,744)*(15,401)*(12,514)*5,139(2,509)*(1,509)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Enanta Pharmaceuticals33,41914,359(9,972)*29.1M19.0 quarters 10-QJun 30, 2026
TuHURA Biosciences996not reported(8,634)*63.7M0.1 quarters 10-QJun 30, 2026
Galectin Therapeutics13,269not reported(2,439)*100.8M5.4 quarters 10-QJun 30, 2026
Protara Therapeutics17,076not reported(15,389)*59.1M9.3 quarters 10-QJun 30, 2026
Cartesian Therapeutics147,6060(21,082)*30.3M7.0 quarters 10-QJun 30, 2026
Caribou Biosciences26,1941,499(22,787)*107.2M4.9 quarters 10-QJun 30, 2026
Fate Therapeutics32,4292,082(23,400)119.8M6.6 quarters 10-QJun 30, 2026
Protalix BioTherapeutics27,42019,896(10,400)*80.6M2.6 quarters 10-QJun 30, 2026
Atossa Therapeutics26,094not reported(9,644)*10.0M2.7 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.